Plus   Neg

Perrigo Profit Tops View, Cuts FY18 Forecast; Plans To Separate Rx Unit

Perrigo Co. plc (PRGO), a healthcare supplier, reported Thursday that its second-quarter net income was $36 million, compared to a net loss of $70 million last year. Earnings per share were $0.26, compared to losses per share of $0.49 last year.

Adjusted net income was $169 million, compared to $175 million a year ago, and adjusted earnings per share were $1.22, same as last year.

Net sales for the quarter fell 4.2 percent to $1.19 billion from $1.24 billion a year earlier. At constant rates, sales dropped 5.7 percent.

On average, analysts polled by Thomson Reuters expected earnings of $1.19 per share on net sales of $1.23 billion for the quarter. Analysts' estimates typically exclude special items.

Looking ahead, the Company now expects calendar year 2018 reported earnings per share to be in the range of $2.11 to $2.31, adjusted earnings per share in the range of $4.75 to $4.95, and net sales in the range of $4.8 billion to $4.9 billion. The revision in outlook is primarily due to revised net sales expectations for the RX segment.

The company previously expected reported earnings per share to be in the range of $2.90 to $3.30, adjusted earnings per share in the range of $5.05 to $5.45, and net sales in the range of $5.0 billion to $5.1 billion.

Analysts expect earnings of $5.2 per share on sales of $5.01 billion for the year.

Separately, Perrigo announced that its Board of Directors approved a plan to separate the Company's Prescription Pharmaceuticals or Rx business following the Company's previously announced strategic portfolio review. The Board will consider all value-enhancing options, including a possible tax-efficient separation to shareholders, a sale or merger.

Further, Perrigo announced that it has entered into a licensing agreement with a subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA for the exclusive rights in the United States to pursue regulatory approval for a non-prescription, over-the-counter Nasonex (mometasone furoate monohydrate) Nasal Spray.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amazon plans to more than double its corporate workforce in Las Vegas by creating 125 additional jobs in the city. The e-commerce giant recently opened a new 30,000 square foot office in Town Square in downtown Las Vegas and plans to expand its corporate workforce in the area to support its Human Resources division. Amazon also said it will donate $100,000 to two food bank partners. Consumer Reports has once again recommended Tesla's Model 3 and Model S sedans as reliable, after the vehicles were previous downgraded by the organization. Consumer Reports said that the two sedans regained its recommendation due to improved reliability reports from owners of the cars, based on the results of its annual Auto Reliability Survey that were announced Thursday. Sears Holdings recalled about 700 units of Kenmore Elite microwave ovens for possible electrical burn hazard, a statement by the U.S. Consumer Product Safety Commission said. The company said the incorrect wiring of the microwave oven causes its exterior to reach temperatures exceeding 183 degrees fahrenheit that could result in a burn hazard to the user.
Follow RTT